Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Cost of Revenue for 18 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue fell 4.1% year-over-year to $2.0 billion; the trailing twelve-month figure through Jun 2026 stood at $8.2 billion (down 1.77% YoY), and the FY2025 full-year result was $8.3 billion, down 1.9% from the prior year.
• Cost of Revenue eased to $2.0 billion in Q2 2026 per TEVA's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Cost of Revenue topped out at $2.2 billion in Q3 2024 and bottomed at $1.9 billion in Q1 2022.
• Historically, Cost of Revenue has averaged $2.1 billion across 5 years, with a median of $2.1 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue fell 8.7% in 2022, then grew 9.2% in 2024.
• Over 5 years, Cost of Revenue stood at $2.1 billion in 2022, then retreated by 3.41% to $2.0 billion in 2023, then increased by 3.33% to $2.1 billion in 2024, then fell by 2.51% to $2.1 billion in 2025, then slipped by 3.26% to $2.0 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $2.0 billion, $2.0 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.